Aliya Omer

Rob Dillard

DocwireNews

Recently, AstraZeneca and Merck &amp; Co., Inc. announced updated results from the OlympiA Phase III trial of Lynparza (olaparib) in early breast cancer at the San Antonio Breast Cancer Symposium (SABCS). Olaparib is the first and only PARP inhibitor to improve survival in this setting.
Olaparib demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) at six years for patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer. It also reduced the risk of death by 28% in these patients.
The safety and tolerability profile of olaparib was in line with that observed in prior clinical trials and no new safety signals were identified with longer follow-up.
DocWire News spoke with Aliya Omer, VP, US Franchise Head, Breast Cancer, about the clinical implications of the findings.

Emily Menendez

Cytokine-Induced Killer Cells Boost RFS, CSS in HCC in Extended Follow-Up

Liver Cancer

DEEPER Trial Final Analysis: m-FOLFOXIRI, Cetuximab Boosts PFS, OS in mCRC

Colorectal Cancer

Christopher Lieu, MD

ASCO GI Studies to Monitor

Latest News

OlympiA Study Demonstrates the Efficacy of Olaparib in the Treatment of Early Breast Cancer

Breast Cancer News

Aliya Omer, AstraZeneca, talks about data that backs the efficacy of olaparib in treating high-risk early breast cancer.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe